Date
12 October 2017
Can the Antimicrobial Resistance Benchmark blaze a new trail?
In a piece for the Lancet, co-authored with Marc Mendelson (Professor of Infectious Diseases and Head of the Division of Infectious Diseases & HIV Medicine, University of Cape Town), Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, discusses the potential of the new Antimicrobial Resistance Benchmark to stimulate pharmaceutical companies to limit antimicrobial resistance.
Direct links
The Antimicrobial Resistance Benchmark is the first independently developed framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance (AMR). It was developed through consultation with stakeholders and experts working in AMR to build consensus on the priorities for pharmaceutical companies in AMR.
Read the article on the Lancet website.